Abstract 2356
Background
Despite several drugs approved in advanced renal cell carcinoma (RCC), new targets are needed as patients frequently experience progression on current approved therapies. TIM-1 is highly upregulated in RCC. CDX-014 combines a tumour targeting antibody against the mucin stalk of TIM-1 with potent cytotoxic microtubule inhibitor monomethyl E (MMAE) using a valine-citrulline peptide linker.
Methods
In this first-in-human phase I trial, patients with advanced clear cell or papillary RCC with at least 2 prior therapies including one vascular endothelial growth factor targeted therapy received CDX-014 every 3 weeks with tumor assessment every 6 weeks. Starting dose was 0.15 mg/kg to be escalated to 1.2 mg/kg in single patient cohorts. Further dose escalations up to 2.4 mg/kg was to follow traditional 3 + 3 design. Protocol was amended after escalation through 2 mg/kg to allow for 1.2 mg/kg dose given every 2 weeks in attempt to improve efficacy without increase in toxicity.
Results
Sixteen patients were enrolled (Table); median number of prior therapies was 4 (range 2-9.) Median number of doses received was 4; 9 patients were on treatment < 3 months. 2 patients remained on therapy for > 1 year. Overall response rate was 6.25% with a partial response (PR) seen at 0.30 mg/kg dose lasting 21 months. Tumor shrinkage and progressive disease (PD) as best response occurred in 5 and 6 patients respectively. Clinical benefit rate (PR or Stable disease (SD) ≥6 months) was 25%. TIM-1 expression was noted in > 10% of tumour cells in 13 patients; none of the remaining 3 patients had any tumour shrinkage. 5 dose limiting toxicities were observed in 2 patients, both at 2 mg/kg. Single grade 5 serious adverse event was associated with high free levels of MMAE. Most common Grade ≥ 3 treatment related adverse event was hyperglycemia occurring in 3 patients.Table:
953P
Dose (mg/kg) every 3 weeks unless specified | # patients enrolled | Best overall response |
---|---|---|
0.15 | 1 | PD |
0.3 | 1 | PR |
0.6 | 1 | PD |
1.2 | 1 | SD |
1.8 | 6 | 5 SD 1 PD |
2 | 4 | 2 SD 1 PD 1 NE |
1.2 q2wks | 2 | 2 PD |
NE=not evaluable.
Conclusions
TIM-1 is a novel target in the treatment of RCC. Optimal dosing strategy of CX-104 has not yet been defined.
Clinical trial identification
NCT02837991.
Editorial acknowledgement
Legal entity responsible for the study
Celldex Pharmaceuticals.
Funding
Celldex Pharmaceuticals.
Disclosure
B.A. McGregor: Honoraria (self), Advisory / Consultancy: EMD Serrano; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Seattle Genetics; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Honoraria (self), Advisory / Consultancy: Janssen; Research grant / Funding (institution): BMS. N. Agarwal: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Argos; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Clovis; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Exelixis; Honoraria (self), Advisory / Consultancy: EMD Serono; Honoraria (self), Advisory / Consultancy: Ely Lilly; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Medivation; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Nektar; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Pharmacyclics. S. George: Honoraria (self), Research grant / Funding (institution): BMS; Honoraria (self), Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Novartis; Honoraria (self): Exelixis; Honoraria (self): Janssen; Honoraria (self), Research grant / Funding (institution): Corvus; Honoraria (self): Genentech; Honoraria (self): Sanofi/Genzyme; Honoraria (self), Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Acceleron; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Eisai; Honoraria (self): EMD Serono. D.I. Quinn: Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self): BMS; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Dendreon; Honoraria (self), Advisory / Consultancy: Exelixis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self): Janssen; Honoraria (self): Novartis; Honoraria (self): Mundipharma; Honoraria (self): Pharmacyclics; Honoraria (self), Advisory / Consultancy: Clovis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Amgen; Advisory / Consultancy: Eisai; Advisory / Consultancy: Novartis; Research grant / Funding (institution), in addition to Millennium: GlaxoSmithKline. M. Rogalski: Full / Part-time employment: Celldex Pharmaceuticals. T. Keler: Full / Part-time employment: Celldex Pharmaceuticals. T. Hawthorne: Full / Part-time employment: Celldex Pharmaceuticals. T.K. Choueiri: Honoraria (self): AstraZeneca; Honoraria (self): Alexion; Honoraria (self): Bayer; Honoraria (self): Bristol Myers-Squibb; Honoraria (self): Cerulean; Honoraria (self): Eisai; Honoraria (self): foundation medication; Honoraria (self): Exelixis; Honoraria (self): Ipsen; Honoraria (self): Tracon; Honoraria (self): Genentech; Honoraria (self): Roche; Honoraria (self): GlaxoSmithKline; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Peloton; Honoraria (self): Pfizer; Honoraria (self): Prometheus labs; Honoraria (self): Corvus. All other authors have declared no conflicts of interest.
Resources from the same session
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract